Sirolimus-eluting stents for treatment of in-stent restenosis immediate and late results

Texas Heart Institute Journal

Volumn 32, Issue 1, 2005, Pages 11-15

  Medina, Alfonso ^a   De Lezo, José Suárez ^b   Pan, Manuel ^b   Delgado, Antonio ^a   Segura, José ^b   Pavlovic, Djordje ^b   Melián, Francisco ^a   Romero, Miguel ^b   Segura, Federico ^a   Hernández, Enrique ^a   Ureña, Isabel ^b   Herrador, Juan ^b  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Coronary restenosis drug therapy pathology prevention control; Delayed action preparations; Drug implants adverse effects; Graft occlusion, vascular; Human; Prevention control; Recurrence prevention control; Sirolimus therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; LOW MOLECULAR WEIGHT HEPARIN; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; CAUSE OF DEATH; CLINICAL FEATURE; DRUG ELUTING STENT; FEMALE; GRAFT OCCLUSION; HEART INFARCTION; HUMAN; INTRAVASCULAR ULTRASOUND; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; STENT; THROMBOSIS; TREATMENT OUTCOME;

AGED; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROSPECTIVE STUDIES; SIROLIMUS; STENTS; TIME FACTORS;

EID: 20044372723     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003;89: 218-24.
2. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, et al, Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107(1)-24-7.
3. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, Carlier SJ, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003;41:184-9.
4. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107:559-64.
5. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610-3.
6. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003; 107:517-20.
7. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107: 381-3.
8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
9. Limpijankit T, Mehran R, Mintz GS, Dangas G, Lansky AJ, Kao J, et al. Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III). Am J Cardiol 2003;92: 315-8.
10. Costa MA, Sabate M, van der Giessen WJ, Kay IP, Cervinka P, Ligthart JM, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999;100:789-92.